Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26135888 | 0.97 | KMT2A (0.47) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL3159987 | 0.97 | HTR6 (0.41) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL1400974 | 0.88 | HTR6 (0.50) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL336575 | 0.88 | HTR6 (0.50) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL1400723 | 0.87 | HTR6 (0.56) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL31208620 | 0.87 | HTR6 (0.56) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL4821430 | 0.87 | HTR6 (0.45) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL3164399 | 0.87 | HTR6 (0.45) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| SCHEMBL6395460 | 0.86 | HTR6 (0.54) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 | |
| Hydrochloric Acid SCHEMBL31605521 | 0.86 | KMT2A (0.52) | KMT2AHPGDSMN1; SMN2HTR6L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704848-A1 | EGFR INHIBITOR FOR TREATING CANCERS COMPRISING ATYPICAL EGFR MUTATIONS | Oric Pharmaceuticals, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4611902-A1 | MALONATE AND GLYCOLATE SALTS OF AN EGFR INHIBITOR | Oric Pharmaceuticals, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612147-A1 | FUMARATE, TARTRATE, MALATE, AND CITRATE SALTS OF AN EGFR INHIBITOR | Voronoi Inc. (KR) | 2025-09-10 | — | — | EP | disclosed |
| CN-120035590-A | Fumarate, tartrate, malate and citrate salts of EGFR inhibitors | 株式会社沃若诺伊 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024233313-A1 | EGFR INHIBITOR FOR TREATING CANCERS COMPRISING ATYPICAL EGFR MUTATIONS | ORIC PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024097848-A1 | MALONATE AND GLYCOLATE SALTS OF AN EGFR INHIBITOR | ORIC PHARMACEUTICALS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096624-A1 | FUMARATE, TARTRATE, MALATE, AND CITRATE SALTS OF AN EGFR INHIBITOR | VORONOI INC. (KR) | 2024-05-10 | — | — | WO | disclosed |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| CN-116194111-A | Heteroaryl derivatives, process for preparing the same, and pharmaceutical compositions containing the same as active ingredient | 株式会社沃若诺伊生物 | 2023-05-30 | — | — | CN | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| EP-1737842-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| CN-1764661-A | Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain | FOURNIER LAB SA (FR) | 2006-04-26 | — | — | CN | disclosed |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005100343-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | KMT2A 4041/4885HPGD 28/4885SMN1; SMN2 1897/4885 |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | KMT2A 4822/4885HPGD 473/4885SMN1; SMN2 3995/4885 |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | KMT2A 4822/4885HPGD 473/4885SMN1; SMN2 3995/4885 |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB4, ERBB2, ERBB3 | KMT2A 1461/4885HPGD 1627/4885SMN1; SMN2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.